Regeneration in a degenerating brain: Potential of allopregnanolone as a neuroregenerative agent

Current Alzheimer Research

Volumn 4, Issue 5, 2007, Pages 510-517

  Jun, Ming Wang ^a   Irwin, Ronald W ^a   Liu, Lifei ^a   Chen, Shuhua ^a   Brinton, Roberta Diaz ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; AMYLOID BETA PROTEIN; NEUROPROTECTIVE AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN DEGENERATION; BRAIN REGION; CALCIUM CELL LEVEL; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; NERVE FIBER REGENERATION; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; PREGNANOLONE; RATS; TAU PROTEINS;

EID: 37049027768     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507783018262     Document Type: Conference Paper

References (82)

1. Bernardi F, Lanzone A, Cento RM, Spada RS, Pezzani I, Genazzani AD, et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 142(5): 466-471 (2000).
2. Bernardi F, Salvestroni C, Casarosa E, Nappi RE, Lanzone A, Luisi S, et al. Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats. Eur J Endocrinol 138(3): 316-321 (1998).
3. Smith CD, Wekstein DR, Markesbery WR, Frye CA. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl) 186(3): 481-485 (2006).
4. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 87(11): 5138-5143 (2002).
5. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, et al. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 60(12): 1287-1294 (2006).
6. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25(19): 4706-4718 (2005).
7. Gage FH. Brain, repair yourself. Sci Am 289(3): 46-53 (2003).
8. Gage FH, Kempermann G, Palmer TD, Peterson DA, Ray J. Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol 36(2): 249-266 (1998).
9. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 16(6): 2027-2033 (1996).
10. Rao MS, Hattiangady B, Abdel-Rahman A, Stanley DP, Shetty AK. Newly born cells in the ageing dentate gyrus display normal migration, survival and neuronal fate choice but endure retarded early maturation. Eur J Neurosci 21(2): 464-476 (2005).
11. Rao MS, Hattiangady B, Shetty AK. The window and mechanisms of major age-related decline in the production of new neurons within the dentate gyrus of the hippocampus. Aging Cell 5(6): 545-558 (2006).
12. Hattiangady B, Rao MS, Shetty GA, Shetty AK. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp Neurol 195(2): 353-371 (2005).
13. Rao MS, Hattiangady B, Reddy DS, Shetty AK. Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy. J Neurosci Res 83(6): 1088-1105 (2006).
14. Rao MS, Hattiangady B, Shetty AK. Fetal hippocampal CA3 cell grafts enriched with FGF-2 and BDNF exhibit robust long-term survival and integration and suppress aberrant mossy fiber sprouting in the injured middle-aged hippocampus. Neurobiol Dis 21(2): 276-290 (2006).
15. Bernal GM, Peterson DA. Neural stem cells as therapeutic agents for age-related brain repair. Aging Cell 3(6): 345-351 (2004).
16. Hallbergson AF, Gnatenco C, Peterson DA. Neurogenesis and brain injury: managing a renewable resource for repair. J Clin Invest 112(8): 1128-1133 (2003).
17. Peterson DA. Stem cell therapy for neurological disease and injury. Panminerva Med 46(1): 75-80 (2004).
18. Peterson DA. Stem cells in brain plasticity and repair. Curr Opin Pharmacol 2(1): 34-42 (2002).
19. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci 17(15): 5820-5829 (1997).
20. Shetty AK, Hattiangady B, Shetty GA. Stem/progenitor cell proliferation factors FGF-2, IGF-1, and VEGF exhibit early decline during the course of aging in the hippocampus: Role of astrocytes. Glia 51(3): 173-86 (2005).
21. Gago N, El-Etr M, Sananes N, Cadepond F, Samuel D, Avellana-Adalid V, Baron-Van Evercooren A, Schumacher M. 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res 78(6): 770-783 (2004).
22. Taupin P, Ray J, Fischer WH, Suhr ST, Hakansson K, Grubb A, et al. FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron 28(2): 385-397 (2000).
23. Brinton RD, Wang JM, Irwin WR, Liu L, Chen S, Wu TW: Allopregnanolone promotes neurogenesis in the triple transgenic AD mouse dentate gyrus and subventricular zone. In The Endocrine Society's 88 Annual Meeting June 23-27; Boston (2006).
24. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 52(1-32 (1997).
25. Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Inter Rev Neurobiol 46: 1-32 (2001).
26. Mellon SH, Griffin LD. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 13(1): 35-43 (2002).
27. Mellon SH, Griffin LD. Synthesis, regulation, and function of neurosteroids. Endocr Res 28(4): 463 (2002).
28. Baulieu EE, Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 37(3): 395-403 (1990).
29. Stoffel-Wagner B, Watzka M, Steckelbroeck S, Ludwig M, Clusmann H, Bidlingmaier F, et al. Allopregnanolone serum levels and expression of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase isoforms in hippocampal and temporal cortex of patients with epilepsy. Epilepsy Res 54(1): 11-19 (2003).
30. Lauber ME, Lichtensteiger W. Ontogeny of 5 alpha-reductase (type 1) messenger ribonucleic acid expression in rat brain: early presence in germinal zones. Endocrinology 137(7): 2718-2730 (1996).
31. Melcangi RC, Froelichsthal P, Martini L, Vescovi AL. Steroid metabolizing enzymes in pluripotential progenitor central nervous system cells: effect of differentiation and maturation. Neuroscience 72(2): 467-475 (1996).
32. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 83(6): 2099-2103 (1998).
33. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 87(11): 5138-5143 (2002).
34. Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, et al. Characterization of brain neurons that express enzymes medi ating neurosteroid biosynthesis. Proc Natl Acad Sci USA 103(39): 14602-14607 (2006).
35. Pinna G, Agis-Balboa RC, Doueiri MS, Guidotti A, Costa E. Brain neurosteroids in gender-related aggression induced by social isolation. Crit Rev Neurobiol 16(1-2): 75-82 (2004).
36. Pomata PE, Colman-Lerner AA, Baranao JL, Fiszman ML. In vivo evidences of early neurosteroid synthesis in the developing rat central nervous system and placenta. Brain Res Dev Brain Res 120(1): 83-86 (2000).
37. Nguyen PN, Ross Young I, Walker DW, Hirst JJ. Allopregnanolone in the brain and blood after disruption of the hypothalamic-pituitary-adrenal axis in fetal sheep. J Endocrinol 182(1): 81-88 (2004).
38. Nguyen PN, Yan EB, Castillo-Melendez M, Walker DW, Hirst JJ. Increased allopregnanolone levels in the fetal sheep brain following umbilical cord occlusion. J Physiol 560(Pt 2): 593-602 (2004).
39. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18(8): 2801-2807 (1998).
40. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7(5): 695-702 (1991).
41. Terry RD, Davies P. Dementia of the Alzheimer type. Annu Rev Neurosci 3: 77-95 (1980).
42. Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly - an update. J Alzheimers Dis 9(3 Suppl): 61-70 (2006).
43. Iqbal K, Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9(3 Suppl: 219-242 (2006).
44. Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 495(1): 70-83 (2006).
45. Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32(5): 911-926 (2001).
46. Finch CE, Morgan TE, Rozovsky I, Xie Z, Weindruch R, Prolla T. Microglia and aging in the brain. In Microglia in the regenerating and degenerating central nervous system (Ed: Streit W). Springer-Verlag, (2002). .
47. Morgan TE, Wong AM, Finch CE. Anti-inflammatory mechanisms of dietary restriction in slowing aging processes. Interdiscip Top Gerontol 35: 83-97 (2007).
48. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 56(4): 259-262 (1989).
49. Eikelenboom P, Rozemuller JM, Kraal G, Stam FC, McBride PA, Bruce ME, et al. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell Pathol Incl Mol Pathol 60(5): 329-336 (1991).
50. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (Berl) 57(2-3): 239-242 (1982).
51. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21(8): 2661-2668 (2001).
52. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23(7): 2557-2563 (2003).
53. Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci 26(3): 775-784 (2006).
54. Herrup K, Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J Alzheimers Dis 4(3): 243-247 (2002).
55. Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 24(42): 9232-9239 (2004).
56. Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol 163(1): 27-33 (2003).
57. Chen Y, McPhie DL, Hirschberg J, Neve RL. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 275(12): 8929-8935 (2000).
58. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 23(17): 6914-6927 (2003).
59. McPhie DL, Golde T, Eckman CB, Yager D, Brant JB, Neve RL. Beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. Brain Res Mol Brain Res 97(1): 103-113 (2001).
60. Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 153(1): 13-17 (2004).
61. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3): 409-421 (2003).
62. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 168(1): 184-194 (2006).
63. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281(3): 1599-1604 (2006).
64. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3): 321-332 (2004).
65. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24(8): 1063-1070 (2003).
66. Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188(1): 52-64 (2004).
67. Brinton RD, Wang JM, Irwin WR, Liu L, Chen S, Wu TW. Promotion of neurogenesis in the triple transgenic alzheimer's mouse dentate gyrus and subventricular zone by the neurosteroid allopregnanolone. In The 10th International Conference of Alzheimer's Disease and Related Disorders. July 15-20; Madrid, Spain.(2006).
68. Son M, Brinton RD. Allopregnanolone induces a rapid transient rise in intracellular calcium in embryonic hippocampal neurons. In The Society for Neuroscience 32 Annual Meeting; Orlando, FL (2002).
69. Ahmad I, Lope-Piedrafita S, Bi X, Hicks C, Yao Y, Yu C, et al. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res 82(6): 811-821 (2005).
70. Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10(7): 704-711 (2004).
71. Mellon S, Gong W, Griffin LD. Niemann pick type C disease as a model for defects in neurosteroidogenesis. Endocr Res 30(4): 727-735 (2004).
72. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277(5323): 228-231 (1997).
73. Neufeld EB, Wastney M, Patel S, Suresh S, Cooney AM, Dwyer NK, et al. The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem 274(14): 9627-9635 (1999).
74. Blanchette-Mackie EJ, Dwyer NK, Amende LM, Kruth HS, Butler JD, Sokol J, et al. Type-C Niemann-Pick disease: low density lipoprotein uptake is associated with premature cholesterol accumulation in the Golgi complex and excessive cholesterol storage in lysosomes. Proc Natl Acad Sci USA 85(21): 8022-8026 (1988).
75. Garver WS, Heidenreich RA. The Niemann-Pick C proteins and trafficking of cholesterol through the late endosomal/lysosomal system. Curr Mol Med 2(5): 485-505 (2002).
76. Garver WS, Somers K, Krishnan K, Mitchell T, Heidenreich RA, Thrall MA. The Niemann-Pick C1 protein in feline fibroblasts. Mol Genet Metab 76(1): 31-36 (2002).
77. Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 44: 399-421 (2004).
78. Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 3(6): 537-544 (2000).
79. Freed CR. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease? Proc Natl Acad Sci USA 99(4): 1755-1757 (2002).
80. Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 250 (Suppl 3) I44-46 (2003).
81. Freed WJ. A perspective on transplantation therapy and stem cells for Parkinson's disease. Cell Transplant 13(3): 319-327 (2004).
82. Greene PE, Fahn S. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus 13(5): e3 (2002).